Optogenetics is emerging as a promising gene therapy for advanced inherited retinal diseases (IRDs) like retinitis pigmentosa, Stargardt disease, and Leber congenital amaurosis. By introducing light-sensitive opsins into surviving retinal cells, this approach aims to restore visual function even in the absence of functional rods and cones. Notably, optogenetic therapies are mutation-agnostic, offering potential benefits across various IRD subtypes. The field is advancing rapidly, with several clinical trials underway to assess the efficacy and safety of optogenetic interventions in patients with late-stage retinal degeneration.
Source: Retinal Physician